Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지
DOI QR코드

DOI QR Code

Indoxyl sulfate, homocysteine, and antioxidant capacities in patients at different stages of chronic kidney disease

  • Chen, Cheng-Hsu (Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital) ;
  • Huang, Shih-Chien (Department of Nutrition, Chung Shan Medical University) ;
  • Yeh, En-Ling (Department of Nutrition, College of Medical and Health Care, Hung-Kuang University) ;
  • Lin, Pei-Chih (Department of Nutrition, Chung Shan Medical University) ;
  • Tsai, Shang-Feng (Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital) ;
  • Huang, Yi-Chia (Department of Nutrition, Chung Shan Medical University)
  • Received : 2021.07.08
  • Accepted : 2021.10.29
  • Published : 2022.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

BACKGROUND/OBJECTIVES: Increased levels of uremic toxins and decreased antioxidant capacity have a significant impact on the progression of chronic kidney disease (CKD). However, it remains unclear whether they interact with each other to mediate the damage of kidney function. The purpose of this study was to investigate whether uremic toxins (i.e., homocysteine and indoxyl sulfate [IS]), as well as glutathione-dependent antioxidant enzyme activities are dependently or independently associated with kidney function during different stages of CKD patients. SUBJECTS/METHODS: One hundred thirty-two patients diagnosed with CKD at stages 1 to 5 participated in this cross-sectional study. RESULTS: Patients who had reached an advanced CKD stage experienced an increase in plasma uremic toxin levels, along with decreased glutathione peroxidase (GSH-Px) activity. Plasma homocysteine, cysteine, and IS concentrations were all positively associated with each other, but negatively correlated to GSH-Px activity levels after adjusting for potential confounders in all CKD patients. Although plasma homocysteine, cysteine, IS, and GSH-Px levels were significantly associated with kidney function, only plasma IS levels still had a significant association with kidney function after these parameters were simultaneously adjusted. In addition, plasma IS could interact with GSH-Px activity to be associated with kidney function. CONCLUSIONS: IS plays a more dominant role than homocysteine and GSH-Px activity in relation to kidney function.

Keywords

Acknowledgement

This study was supported by Taichung Veterans General Hospital (TCVGH-1083601B, TCVGH-VHCY1088602), Taiwan. This manuscript has been submitted as a preprint in Research Square at the link below: https://www.researchsquare.com/article/rs-41393/v1.

References

  1. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43. https://doi.org/10.1046/j.1523-1755.2003.00924.x
  2. Rossi M, Campbell KL, Johnson DW. Indoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxins. OA Nephrol 2013;1:13.
  3. Vanholder R, De Smet R, Lameire N. Protein-bound uremic solutes: the forgotten toxins. Kidney Int Suppl 2001;78:S266-70. https://doi.org/10.1046/j.1523-1755.2001.59780266.x
  4. Liu WC, Tomino Y, Lu KC. Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120. Toxins (Basel) 2018;10:367. https://doi.org/10.3390/toxins10090367
  5. Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010;72:1-11.
  6. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, Wu CJ. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011;25:191-7. https://doi.org/10.1002/jcla.20456
  7. Levi A, Cohen E, Levi M, Goldberg E, Garty M, Krause I. Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: a historical prospective study. Eur J Intern Med 2014;25:951-5. https://doi.org/10.1016/j.ejim.2014.10.014
  8. Chen CH, Yang WC, Hsiao YH, Huang SC, Huang YC. High homocysteine, low vitamin B-6, and increased oxidative stress are independently associated with the risk of chronic kidney disease. Nutrition 2016;32:236-41. https://doi.org/10.1016/j.nut.2015.08.016
  9. Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. Med Hypotheses 2011;77:1088-93. https://doi.org/10.1016/j.mehy.2011.09.009
  10. Long Y, Nie J. Homocysteine in renal injury. Kidney Dis (Basel) 2016;2:80-7. https://doi.org/10.1159/000444900
  11. Sun CY, Hsu HH, Wu MS. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant 2013;28:70-8. https://doi.org/10.1093/ndt/gfs133
  12. Gouroju S, Rao PVLNS, Bitla AR, Vinapamula KS, Manohar SM, Vishnubhotla S. Role of gut-derived uremic toxins on oxidative stress and inflammation in patients with chronic kidney disease. Indian J Nephrol 2017;27:359-64. https://doi.org/10.4103/ijn.IJN_71_17
  13. Stoyanova E, Sandoval SB, Zuniga LA, El-Yamani N, Coll E, Pastor S, Reyes J, Andres E, Ballarin J, Xamena N, et al. Oxidative DNA damage in chronic renal failure patients. Nephrol Dial Transplant 2010;25:879-85. https://doi.org/10.1093/ndt/gfp575
  14. Sahni N, Gupta KL, Rana SV, Prasad R, Bhalla AK. Intake of antioxidants and their status in chronic kidney disease patients. J Ren Nutr 2012;22:389-99. https://doi.org/10.1053/j.jrn.2011.09.002
  15. Sung CC, Hsu YC, Chen CC, Lin YF, Wu CC. Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease. Oxid Med Cell Longev 2013;2013:301982. https://doi.org/10.1155/2013/301982
  16. Xu G, Luo K, Liu H, Huang T, Fang X, Tu W. The progress of inflammation and oxidative stress in patients with chronic kidney disease. Ren Fail 2015;37:45-9. https://doi.org/10.3109/0886022X.2014.964141
  17. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, Takahashi K, Palmer IS, Cohen HJ. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994;266:C367-75. https://doi.org/10.1152/ajpcell.1994.266.2.C367
  18. Brown KM, Arthur JR. Selenium, selenoproteins and human health: a review. Public Health Nutr 2001;4:593-9. https://doi.org/10.1079/PHN2001143
  19. Zachara BA, Salak A, Koterska D, Manitius J, Wasowicz W. Selenium and glutathione peroxidases in blood of patients with different stages of chronic renal failure. J Trace Elem Med Biol 2004;17:291-9. https://doi.org/10.1016/S0946-672X(04)80031-2
  20. Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, Beddhu S, Roberts WL. Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. Ann Clin Lab Sci 2011;41:331-9.
  21. Zargari M, Sedighi O. Influence of hemodialysis on lipid peroxidation, enzymatic and non-enzymatic antioxidant capacity n chronic renal failure patients. Nephrourol Mon 2015;7:e28526.
  22. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-38. https://doi.org/10.1046/j.1523-1755.2002.00600.x
  23. Khazim K, Giustarini D, Rossi R, Verkaik D, Cornell JE, Cunningham SED, Mohammad M, Trochta K, Lorenzo C, Folli F, et al. Glutathione redox potential is low and glutathionylated and cysteinylated hemoglobin levels are elevated in maintenance hemodialysis patients. Transl Res 2013;162:16-25. https://doi.org/10.1016/j.trsl.2012.12.014
  24. Tucker PS, Dalbo VJ, Han T, Kingsley MI. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers 2013;18:103-15. https://doi.org/10.3109/1354750X.2012.749302
  25. KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150. https://doi.org/10.1038/kisup.2012.73
  26. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr A 1987;422:43-52. https://doi.org/10.1016/0378-4347(87)80438-3
  27. Cheng FP, Hsieh MJ, Chou CC, Hsu WL, Lee YJ. Detection of indoxyl sulfate levels in dogs and cats suffering from naturally occurring kidney diseases. Vet J 2015;205:399-403. https://doi.org/10.1016/j.tvjl.2015.04.017
  28. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med 2001;31:331-5. https://doi.org/10.1016/S0891-5849(01)00584-6
  29. Arnao MB, Cano A, Hernandez-Ruiz J, Garcia-Canovas F, Acosta M. Inhibition by L-ascorbic acid and other antioxidants of the 2.2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) oxidation catalyzed by peroxidase: a new approach for determining total antioxidant status of foods. Anal Biochem 1996;236:255-61. https://doi.org/10.1006/abio.1996.0164
  30. Zachara BA, Adamowicz A, Trafikowska U, Pilecki A, Manitius J. Decreased plasma glutathione peroxidase activity in uraemic patients. Nephron 2000;84:278-81. https://doi.org/10.1159/000045591
  31. Kuchta A, Pacanis A, Kortas-Stempak B, Cwiklinska A, Zietkiewicz M, Renke M, Rutkowski B. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res 2011;34:12-9. https://doi.org/10.1159/000321508
  32. Zachara BA, Gromadzinska J, Wasowicz W, Zbrog Z. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006;53:663-77. https://doi.org/10.18388/abp.2006_3294
  33. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21:845-53. https://doi.org/10.1016/0891-5849(96)00233-X
  34. Lasseur C, Parrot F, Delmas Y, Level C, Ged C, Redonnet-Vernhet I, Montaudon D, Combe C, Chauveau P. Impact of high-flux/high-efficiency dialysis on folate and homocysteine metabolism. J Nephrol 2001;14:32-5.
  35. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-6. https://doi.org/10.1097/01.ASN.0000110181.64655.6C
  36. Rossi M, Campbell K, Johnson D, Stanton T, Pascoe E, Hawley C, Dimeski G, McWhinney B, Ungerer J, Isbel N. Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study. Nutr Metab Cardiovasc Dis 2014;24:1035-42. https://doi.org/10.1016/j.numecd.2014.04.006
  37. Xie T, Bao M, Zhang P, Jiao X, Zou J, Ding X, Cao X, Yu X. Serum concentration of indoxyl sulfate in peritoneal dialysis patients and low-flux hemodialysis patients. Blood Purif 2019;48:183-90. https://doi.org/10.1159/000499749
  38. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 2014;25:1897-907. https://doi.org/10.1681/ASN.2013101062
  39. Milanesi S, Garibaldi S, Saio M, Ghigliotti G, Picciotto D, Ameri P, Garibotto G, Barisione C, Verzola D. Indoxyl sulfate induces renal fibroblast activation through a targetable heat shock protein 90-dependent pathway. Oxid Med Cell Longev 2019;2019:2050183. https://doi.org/10.1155/2019/2050183
  40. Nakano T, Katsuki S, Chen M, Decano JL, Halu A, Lee LH, Pestana DVS, Kum AST, Kuromoto RK, Golden WS, et al. Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay of OATP2B1 and DII4-Notch signaling. Circulation 2019;139:78-96. https://doi.org/10.1161/circulationaha.118.034588
  41. Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol 2017;18:35. https://doi.org/10.1186/s12882-017-0457-1
  42. Hung SC, Kuo KL, Wu CC, Tarng DC. Indoxyl sulfate: a novel cardiovascular risk factor in chronic kidney disease. J Am Heart Assoc 2017;6:e005022. https://doi.org/10.1161/JAHA.116.005022
  43. Fan PC, Chang JC, Lin CN, Lee CC, Chen YT, Chu PH, Kou G, Lu YA, Yang CW, Chen YC. Serum indoxyl sulfate predicts adverse cardiovascular events in patients with chronic kidney disease. J Formos Med Assoc 2019;118:1099-106. https://doi.org/10.1016/j.jfma.2019.03.005
  44. Barisione C, Ghigliotti G, Canepa M, Balbi M, Brunelli C, Ameri P. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Curr Drug Targets 2015;16:366-72. https://doi.org/10.2174/1389450116666141230114500
  45. Shimizu H, Bolati D, Adijiang A, Muteliefu G, Enomoto A, Nishijima F, Dateki M, Niwa T. NF-κB plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression, and inhibition of proliferation in proximal tubular cells. Am J Physiol Cell Physiol 2011;301:C1201-12. https://doi.org/10.1152/ajpcell.00471.2010
  46. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011;6:30-9. https://doi.org/10.2215/CJN.05340610
  47. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007;5:1302-8. https://doi.org/10.1111/j.1538-7836.2007.02540.x
  48. Sirich TL, Plummer NS, Gardner CD, Hostetter TH, Meyer TW. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin J Am Soc Nephrol 2014;9:1603-10. https://doi.org/10.2215/CJN.00490114
  49. Rossi M, Johnson DW, Xu H, Carrero JJ, Pascoe E, French C, Campbell KL. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutr Metab Cardiovasc Dis 2015;25:860-5. https://doi.org/10.1016/j.numecd.2015.03.015